FDA Panel: Reformulated OxyContin Did Not Reduce Overall Abuse

(MedPage Today) -- An FDA advisory committee overwhelmingly panned the idea that Purdue Pharma's abuse-deterrent formulation (ADF) of oxycodone (OxyContin) "meaningfully reduced" overall opioid abuse, overdose and death.
Just two of the 28 members...